RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Antinociceptive effects of imidazoline I-2 receptor agonists in the formalin test in rats
Thorn, D. A., Qiu, Y., Jia, S., Zhang, Y., & Li, J.-X. (2016). Antinociceptive effects of imidazoline I-2 receptor agonists in the formalin test in rats. Behavioural Pharmacology, 27(4), 377-383. https://doi.org/10.1097/FBP.0000000000000206
he imidazoline I-2 receptor is an emerging drug target for analgesics. This study extended previous studies by examining the antinociceptive effects of three I-2 receptor agonists (2-BFI, BU224, and CR4056) in the formalin test. The receptor mechanisms and anatomical mediation of I-2 receptor agonist-induced antinociception were also examined. Formalin-induced flinching responses (2%, 50 mu l) were quantified after treatment with I-2 receptor agonists alone or in combination with the I-2 receptor antagonist idazoxan. Anatomical mediation was studied by locally administering 2-BFI into the plantar surface or into the right lateral ventricle through cannulae (intracerebroventricular). The locomotor activity was also examined after central (intracerebroventricular) administration of 2-BFI. 2-BFI (1-10 mg/kg, intraperitoneal) and BU224 (1-10 mg/kg, intraperitoneal) attenuated the spontaneous flinching response observed during 10 min (phase 1) and 20-60 min (phase 2) following formalin treatment, whereas CR4056 (1-32 mg/kg, intraperitoneal) decreased only phase 2 flinching response. The I-2 receptor antagonist idazoxan attenuated the antinociceptive effects of 2-BFI and BU224 during phase 1, but not phase 2. Peripheral administration of 2-BFI (1-10 mg/kg, intraplantar) to the hind paw of rats had no antinociceptive effect. In contrast, centrally delivered 2-BFI (10-100 mu g, intracerebroventricular) dose-dependently attenuated phase 1 and phase 2 flinching at doses that did not reduce the locomotor activity. Together, these data revealed the differential antinociceptive effects of I-2 receptor agonists and the differential antagonism profiles by idazoxan, suggesting the involvement of different I-2 receptor subtypes in reducing different phases of formalin-induced pain-like behaviors. In addition, the results also suggest the central mediation of I-2 receptor agonist-induced antinociceptive actions. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
